Determinants of antidepressant treatment compliance: implications for policy.
Depression is among the most prevalent, devastating, and undertreated disorders in our society. Treatment with antidepressant medications is effective in controlling symptoms, but treatment beyond the point of symptom resolution is necessary to restore functional status and prevent recurrent episodes. An important step in improving compliance is to identify the determinants of antidepressant treatment compliance. A broader motivation for our study is to examine compliance by patients with a chronic but treatable disease. With claims data between 1990 and 1993, this study uses logistic regression analysis to examine the determinants of compliance among 2,012 antidepressant recipients. The results show that initiating treatment with a tricyclic antidepressant reduces the probability of antidepressant treatment compliance. Initiating treatment with a selective serotonin reuptake inhibitor and undergoing family, group, or individual psychotherapy treatments increase the probability of compliance. Case management does not meaningfully affect compliance. Implications for policy and clinical practice are discussed.
Tai-Seale
M
M
Indiana University, USA.
Croghan
T W
TW
Obenchain
R
R
D000928:Antidepressive Agents / Q000627:therapeutic use*; D019090:Case Management; D003863:Depression / Q000188:drug therapy*; D017050:Episode of Care; D006301:Health Services Needs and Demand; D006801:Humans; D016015:Logistic Models; D015233:Models, Statistical; D010349:Patient Compliance; D017410:Practice Guidelines as Topic; D015983:Selection Bias; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D014600:Utilization Review
D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors